- Our LinkedIn Page
- Our Twitter Feed
- Our Facebook Page
- Newsletter Subscribe to our e-newsletter. Current Issue
- Our Flickr Feed
- Our YouTube Feed
Tags
biotechnology PUBLIC BIOTECH - Stats Industry Analysis economic development economy BIO International Convention IPO Partnering patent drug development BIOTECH Health Care Events One-on-One's Investment FDA Biotechnology Industry PUBLIC BIOTECH - Stock performance biotech industry 2012 BIO International ConventionAuthors
- Abigail Hirsch
- Alan Eisenberg
- BIOtechNOW Editor
- Bruce Dale
- Celia Economides
- Colleen Lerro
- David Thomas, CFA
- George Goodno
- George MacDougall
- Jason Corum
- Jeff Joseph
- Jim Greenwood
- Karen Batra
- Kelly Cappio
- Lila Feisee
- Matt Carr
- Nathan Schock
- Paul Winters
- Paulina Ibarra
- Robbi Lycett
- Roy Zwahlen
- Sarah Sneeringer
- Sondra Behan
- Stephanie Fischer
- Stephen Marmaras
- Tracy Cooley
Business and Investments
Category Archives: Business and Investments
Latest From Business and Investments
Announcing the Buzz of BIO Winner for Pipelines of Promise!
We’re very pleased to announce the Buzz of BIO Winner for the 2012 contest of the BIO International Convention. You voted for your favorites, and it was a tight, interesting race! As such, we’re pleased to introduce you to our winner for the Pipelines of Promise category. Deuteria Pharmaceuticals, Inc,. who focuses on improving the product profile of approved drugs through ‘chiral switching’, won the Pipelines of Promise category. From Dr. Sheila DeWitt, the company’s Read More >
BioManufacturers Increasing Budgets for New Technologies
By Eric Langer, Managing Partner, BioPlan Associates, Inc. Two-thirds Spending more for Improved Productivity Almost two-thirds (64.2 percent) of biomanufacturers will increase their budgets for new technologies to improve efficiencies and costs for downstream production this year. Data from our newly released 9th Annual Report and Survey of Biopharmaceutical Manufacturers, include responses from 302 global biomanufacturers, and an additional 185 vendors to the industry. We find that budget increases this year are not just incremental Read More >
The Life Sciences Foundation – Telling the Story of Biotechnology
By the Life Sciences Foundation “If a man were permitted to make all the ballads, he need not care who should make the laws of a nation.” – Scottish politician Andrew Fletcher (1653-1716) Why History Matters Biotechnologists are in the tomorrow business. They strive to innovate, invent, and make progress. They must; survival depends on it. Biotechnologists are future-oriented. Yet, biotechnologists are also steeped in history. They swim in the past, and strive constantly to Read More >
Partnering Launches for the International Convention
It’s here folks! The One-on-One Partnering™ System for this year’s BIO Business Forum® and Exhibitor Partnering has officially launched! What does that mean? If you’re registered for the event, you’ll be receiving your login credentials shortly. If you’re not registered, you should do that now, so you can get in to the system. From there, you can start building your company’s profile, search for companies, and send your targeted meeting requests. This year, we’re pleased Read More >
Indices, IPOs, and New Drug Approvals – Update April 3rd 2012
1. Stock Performance. The Nasdaq Biotech Index (NBI) continued to outperform in March, maintaining its Year-to-Date (YTD) lead of 18% vs. 12% for the S&P 500. Concentrated portfolios holding Amlyin, Regeneron, and Illumina came out even higher. For example, the Amex Biotech Index (BTK) is up 29% this year mainly because it held concentrated positions in these names. Amylin (ALMN) has doubled on the FDA approval for Bydureon and post-approval buy-out rumors. Illumina (ILMN) is up 72% Read More >
